If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== Chemistry of saturated vs unsaturated acids === The reactivity of saturated fatty acids is usually associated with the carboxylic acid or the adjacent methylene group. By conversion to their acid chlorides, they can be converted to the symmetrical fatty ketone laurone (O=C(CnH(2n+1))2). Treatment with sulfur trioxide gives the α-sulfonic acids. The reactivity of unsaturated fatty acids is often dominated by the site of unsaturation. These reactions are the basis of ozonolysis, hydrogenation, and the iodine number. Ozonolysis (degradation by ozone) is practiced in the production of azelaic acid ((CH2)7(CO2H)2) from oleic acid.
== Chemical properties == According to food chemist Udo Pollmer of the European Institute of Food and Nutrition Sciences in Munich, alcohol can be absorbed in cyclodextrins, a synthetic carbohydrate derivative. In this way, encapsuled in small capsules, the fluid can be handled as a powder. The cyclodextrins can absorb an estimated 60 percent of their own weight in alcohol. A US patent was registered for the process as early as 1974.
A 2023 review found that men tend to be diagnosed with type 2 diabetes at a younger age and lower BMI, and that women with the condition have a higher relative risk of cardiovascular disease and death than men (although absolute cardiovascular mortality remains higher in men), yet women, particularly younger women, are less likely to receive guideline-recommended cardiovascular risk reduction. Racial and ethnic minorities are disproportionately affected with higher prevalence of diabetes compared to non-minority individuals. While US adults overall have a 40% chance of developing type 2 diabetes, Hispanic/Latino adults chance is more than 50%. African Americans also are much more likely to be diagnosed with diabetes compared to White Americans. Asians have increased risk of diabetes as diabetes can develop at lower BMI due to differences in visceral fat compared to other races. For Asians, diabetes can develop at a younger age and lower body fat compared to other groups. Additionally, diabetes is highly underreported in Asian American people, as 1 in 3 cases are undiagnosed compared to the average 1 in 5 for the nation. People with diabetes who have neuropathic symptoms such as numbness or tingling in feet or hands are twice as likely to be unemployed as those without the symptoms. In 2010, diabetes-related emergency room (ER) visit rates in the United States were higher among people from the lowest income communities (526 per 10,000 population) than from the highest income communities (236 per 10,000 population).
Sources: en.wikipedia.org
===== Digital wallet scheme ===== Paetongtarn has overseen the implementation of the 10,000-baht digital wallet scheme, the flagship economic policy of the Pheu Thai Party. The scheme was originally promised during the 2023 election campaign as a one-time universal handout to nearly all Thais aged 16 and over, intended to deliver a large-scale stimulus to the domestic economy. However, since the Paetongtarn government took office, the program has faced significant modifications, delays, and criticism regarding its funding, implementation, and economic necessity. The initial plan to fund the 500 billion baht scheme through a special loan bill was scrapped due to legal concerns and fears of violating fiscal discipline laws. Instead, the government has relied on the national budget. The universal nature of the handout was also curtailed, with eligibility restrictions introduced to exclude high-income earners (those with an annual income over 840,000 baht) and individuals with more than 500,000 baht in savings. Phase 1, launched in September 2024, provided 10,000 baht in cash to approximately 14.5 million recipients, including state welfare cardholders and individuals with disabilities. Phase 2, implemented between January and April 2025, extended the cash transfers to an estimated 3 million senior citizens aged 60 and over. The first truly "digital" phase, which was set to target around 2.7 million young people aged 16–20 via a government application, has been indefinitely postponed.
prostacyclin synthase to create prostacyclin thromboxane-A synthase to create thromboxane A2 and 12-(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid (HHT) (see 12-Hydroxyheptadecatrienoic acid) prostaglandin D2 synthase to create prostaglandin D2 prostaglandin E synthase to create prostaglandin E2 prostaglandin F synthase to create prostaglandin F2α It rearranges non-enzymatically to:
biomarker A measurable indicator of some biological state, especially a compound or biomolecule whose presence or absence in a biological system is a reliable sign of a normal or abnormal process, condition, or disease. Things that may serve as biomarkers include direct measurements of the concentration of a particular compound or molecule in a tissue or fluid sample, or any other characteristic physiological, histological, or radiographic signal (e.g. a change in heart rate, or a distinct morphology under a microscope). They are regularly used as predictive or diagnostic tools in clinical medicine and laboratory research.
Sources: en.wikipedia.org
Asian citrus psyllid on the UF / IFAS Featured Creatures Web site Species Profile – Citrus Greening and Species Profile – Asian Citrus Psyllid, National Invasive Species Information Center, National Agricultural Library. Lists general information and resources for citrus greening and the Asian citrus psyllid. CISR: Huanglongbing/Citrus Greening Center for Invasive Species Research page on Huanglongbing and Citrus Greening
=== General chemical analysis === Freezing-point depression can be used as a purity analysis tool when analysed by differential scanning calorimetry. This is possible because the temperature range over which a mixture of compounds melts is dependent on their relative amounts. Consequently, less pure compounds will exhibit a broadened melting peak that begins at lower temperature than a pure compound.
=== Overview === The Office of Alternative Medicine (OAM) was established in October 1991 by the United States Congress. The OAM was expanded from an office into a center and renamed the National Center for Complementary and Alternative Medicine (NCCAM) in October 1998. It is one of several centers within the National Institutes of Health (NIH). The founding director of the center was Stephen Straus. In 2008, Josephine Briggs became the second director of NCCAM. The NCCAM was renamed the National Center for Complementary and Integrative Health (NCCIH) in December 2014. Helene Langevin was director from August 2018 to November 2025. The 2014 name change to NCCIH has been described by critics as an attempt by the center to mitigate criticism by avoiding the term "alternative" and distancing itself from having funded studies of questionable merit. The 2001 mission statement of the NCCAM stated that it was "dedicated to exploring complementary and alternative healing practices in the context of rigorous science; training complementary and alternative medicine researchers; and disseminating authoritative information to the public and professionals." As NCCIH, the mission statement is "to define, through rigorous scientific investigation, the usefulness and safety of complementary and alternative medicine interventions and their roles in improving health and health care".
Atoltivimab/maftivimab/odesivimab, sold under the brand name INMAZEB, is a fixed-dose combination of three monoclonal antibodies for the treatment of ebola caused by Zaire ebolavirus. It was developed by Regeneron Pharmaceuticals and contains three human monoclonal antibodies, atoltivimab, maftivimab, and odesivimab-ebgn. The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection. Atoltivimab/maftivimab/odesivimab is the first FDA-approved treatment for Zaire ebolavirus. Atoltivimab/maftivimab/odesivimab was approved for medical use in the United States in October 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines. Atoltivimab/maftivimab/odesivimab is indicated for the treatment of infection caused by Zaire ebolavirus.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.